Clinical trial
The Effects of Aripiprazole on Patients With Metabolic Syndrome
NCT00224822 · New Mexico VA Healthcare System, U.S. Fed · Completed
Key facts
| NCT number | NCT00224822 |
|---|---|
| Title | The Effects of Aripiprazole on Patients With Metabolic Syndrome |
| Official title | The Effects of Aripiprazole on Patients With "Metabolic Syndrome": An Open-Label Trial |
| Lead sponsor | New Mexico VA Healthcare System, U.S. Fed |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Metabolic Syndrome X |
| Intervention type | Drug |
| Interventions | Aripiprazole |
| Enrollment | 27 |
| Start date | Mar 1, 2004 |
| Completion | Mar 1, 2007 |
| First posted | Sep 23, 2005 |
| Last update posted | Mar 24, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: